文献速递结核与非结核分枝杆菌

四个月每日利福平与三个月每日利福平/异烟肼治疗寻求庇护者结核感染的随机对照试验

Four months daily rifampicin vs. 3 months daily rifampicin/isoniazid for the treatment of tuberculosis infection in asylum seekers: a randomized controlled trial.
PubMed 文献 · Clin Microbiol Infect · 2025-03-01

在意大利寻求庇护者中开展的 prospective、open-label、randomized phase 4 superiority trial,比较4R与3HR预防性治疗结核感染的完成率和耐受性。113例随机至4R、112例至3HR,完成率4R组77.9%(95%CI 69.1-85.1)vs 3HR组75.9%(95%CI 66.9-83.5),p 0.7,4R未优于3HR。副作用停药率和总体不良事件率两组无统计学差异。

要点

  • 4R组治疗完成率77.9%(95%CI 69.1-85.1),3HR组75.9%(95%CI 66.9-83.5),p 0.7。
  • 完成治疗的risk ratio为1.03(95%CI 0.89-1.18),risk difference为0.03(95%CI -0.09至0.13),4R未优于3HR。
  • 副作用停药率(4R组25/113 vs 3HR组27/112)和总体不良事件率(4R组47/113 vs 3HR组36/112)两组无统计学差异。

核心结论

  • 在意大利寻求庇护者中,4R在治疗完成率方面未优于3HR。

研究设计与样本

  • prospective、open-label、randomized phase 4 superiority trial,旨在证明4R较3HR完成率至少提高15%。
  • 研究对象为意大利寻求庇护者,经Quantiferon Plus检测结核感染阳性后受邀参与。
  • 2021年6月至2023年7月,113例随机至4R组、112例随机至3HR组。
  • 主要结局为治疗完成率,通过临床访视依从性和药片计数评估。

主要发现

  • 4R组完成治疗88例(77.9%;95%CI 69.1-85.1),3HR组完成治疗85例(75.9%;95%CI 66.9-83.5),p 0.7。
  • 4R组相较3HR组完成治疗的risk ratio为1.03(95%CI 0.89-1.18),risk difference为0.03(95%CI -0.09至0.13)。
  • 因副作用停药:4R组25/113 vs 3HR组27/112,两组无统计学差异。
  • 总体不良事件:4R组47/113 vs 3HR组36/112,两组无统计学差异。

关键数值与推荐

  • WHO推荐4个月每日利福平(4R)和3个月每日异烟肼/利福平(3HR)用于预防性治疗,但无试验直接比较两方案。
  • 研究设计为非劣效/优效性检验,预设4R较3HR完成率至少提高15%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Treatment of tuberculosis (TB) infection is a core intervention of the TB elimination strategy. The WHO recommends both 4 months of daily rifampicin (4R) and 3 months of daily isoniazid/rifampicin (3HR) for preventive therapy, but no trial directly compared the two regimens. We measured the completion rate and tolerability of 4R and 3HR for TB preventive therapy. METHODS: We conducted a prospective, open-label, randomized phase 4 superiority trial to demonstrate an increase of at least 15% in the completion rate of 4R over 3HR among asylum seekers in Italy. Asylum seekers were tested for TB infection by the Quantiferon Plus test and offered to participate in the study if infected. The primary outcome was treatment completion, measured by adherence to clinical visits and pill count. Unadjusted Kaplan-Meier curves were used to compare permanent interruptions in the two arms by days of treatment. Generalized linear model for the binomial family and logit link function was performed to determine factors associated with treatment completion. RESULTS: From June 2021 to July 2023, we randomized 113 individuals to 4R and 112 to 3HR. Treatment was completed by 88 subjects (77.9; 95% CI, 69.1-85.1) in the 4R arm and 85 (75.9; 95% CI, 66.9-83.5) in the 3HR arm (p 0.7). The risk ratio for completing treatment was 1.03 (95% CI, 0.89-1.18) in the 4R arm compared with the 3HR arm with a risk difference of 0.03 (95% CI, -0.09 to 0.13). Dropout rates due to side effects (25/113 in 4R vs. 27/112 in 3HR) and the overall rate of adverse events (47/113 in 4R vs. 36/112 in 3HR) were not statistically different in the two groups. DISCUSSION: 4R was not superior, in terms of completion rate, to 3HR for the treatment of TB infection among asylum seekers in Italy. TRIAL REGISTRATION NUMBER: EudraCT 2021-001438-20.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Matteelli A, Russo G, Rossi L, et al. Four months daily rifampicin vs. 3 months daily rifampicin/isoniazid for the treatment of tuberculosis infection in asylum seekers: a randomized controlled trial. Clin Microbiol Infect. 2025. PMID: 40032083. doi:10.1016/j.cmi.2025.02.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。